Skip to main content
Premium Trial:

Request an Annual Quote

Harry Hixson, Mats-Olof Wallin, George Rathmann, Ted Love, Richard Brewer, Mary Pendergast, Phillipe Chambon, Jean-Francois Formela, Martin Vogelbaum

Premium

Sequenom recruited former Amgen CEO Harry Hixson to its board, the company said Jan. 14. Hixson is currently chairman and CEO of privately held drug firm Elitra Pharmaceuticals.


Pyrosequencing named Mats-Olof Wallin CFO, capping a broad restructuring begun in October.

Wallin, 51, is currently CFO of Ortivus, a Swedish medical technology company. He will oversee Pyrosequencing’s financings in Sweden and in the US.


Hyseq and Variagenics have named six board members and a chairman to oversee the new — and still unnamed — company set to emerge Jan. 28 [see accompanying story, page 3]. From the Hyseq side, Chairman George Rathmann, 75, will retain his title at the new firm. He will be joined on the board by Hyseq compatriots Ted Love, 43; Richard Brewer, 51; and Mary Pendergast, 52. Variagenics, meantime, will chip in Phillipe Chambon, 44; Jean-Francois Formela, 46; and Martin Vogelbaum, 39.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.